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Abstract
Background—Equivalence of laboratory tests over time is important for longitudinal studies. 
Even a small systematic difference (bias) can result in substantial misclassification.
Methods—We selected 200 Atherosclerosis Risk in Communities Study participants attending 
all 5 study visits over 25 years. Eight analytes were re-measured in 2011–13 from stored blood 
samples from multiple visits: creatinine, uric acid, glucose, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides, and high-sensitivity C-reactive protein. Original values were 
recalibrated to re-measured values using Deming regression. Differences >10% were considered 
to reflect substantial bias, and correction equations were applied to affected analytes in the total 
study population. We examined trends in chronic kidney disease (CKD) pre- and post-
recalibration.
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Results—Repeat measures were highly correlated with original values (Pearson’s r>0.85 after 
removing outliers [median 4.5% of paired measurements]), but 2 of 8 analytes (creatinine and uric 
acid) had differences >10%. Original values of creatinine and uric acid were recalibrated to 
current values using correction equations. CKD prevalence differed substantially after 
recalibration of creatinine (visits 1, 2, 4 and 5 pre-recalibration: 21.7%, 36.1%, 3.5%, 29.4%; post-
recalibration: 1.3%, 2.2%, 6.4%, 29.4%). For HDL-cholesterol, the current direct enzymatic 
method differed substantially from magnesium dextran precipitation used during visits 1–4.
Conclusions—Analytes re-measured in samples stored for ~25 years were highly correlated 
with original values, but two of the 8 analytes showed substantial bias at multiple visits. 
Laboratory recalibration improved reproducibility of test results across visits and resulted in 
substantial differences in CKD prevalence. We demonstrate the importance of consistent 
recalibration of laboratory assays in a cohort study.
INTRODUCTION
Equivalence of laboratory measurements over time is of central importance for studies of 
trends in disease prevalence, incidence, and progression. Assay recalibration is especially 
crucial when a disease is defined categorically using biomarker levels above or below a 
certain cut-point. Even a small amount of systematic difference can lead to substantial 
misclassification of disease (1–7). Small differences (e.g. <10%) may have little impact on 
clinical decision-making or classification of individuals with values far from a clinical 
cutoff. However, at the population level, small, systematic differences shift the entire 
distribution of a biomarker, resulting in biased estimates of prevalence and incidence. Large 
epidemiologic studies must carefully assess the recalibration and reproducibility of their 
biomarker measurements to ensure equivalence across study visits to ensure accurate 
comparisons over time.
Leveraging previous experience in the laboratory recalibration of biomarkers in large 
epidemiologic studies (1,2,5,8–10), we undertook recalibration of 8 key laboratory tests in 
the Atherosclerosis Risk in Communities (ARIC) Study. The ARIC Study is a prospective 
cohort with over 25 years of follow-up and five study visits during which blood samples 
were collected. Our objectives were: 1) to assess the equivalence of different biomarker 
measurements across the five ARIC visits, focusing on those where there were changes in 
research laboratories, sample types, and/or measurement procedure; 2) to determine 
recalibration corrections for those analytes lacking equivalence; and 3) to assess trends in 
each analyte before and after recalibration. To illustrate the potential impact of laboratory 
measurement change on prevalence and incidence of an important chronic disease, we 
examined trends in estimated chronic kidney disease (CKD) prevalence as defined from 
creatinine concentrations before and after recalibration in this study population.
METHODS
Study population
The ARIC Study is an ongoing community-based cohort of 15,792 adults who were enrolled 
between 1987 and 1989 from four communities in the United States (11). Participants have 
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been invited to four follow-up examinations (visits 2 through 5 which took place during 
1990–92, 1993–95, 1996–98 and 2011–13, respectively). An institutional review board at 
each site approved all procedures, and all study participants provided written informed 
consent.
We selected a subsample of participants for re-measurement of biomarkers in stored blood 
samples. Among participants who had plasma samples available at all five visits, 200 were 
selected using stratified random sampling within 16 strata based on 5-year baseline age 
categories (45–49 years, 50–54 years, 55–59 years, and 60–65 years), gender, and race/
ethnicity (white or black). The purpose of stratified random sampling was to have the 
distribution of these characteristics in the recalibration subsample broadly reflect that in the 
full ARIC cohort.
Laboratory Measurement Procedures
A total of 8 analytes were included in the main recalibration study: creatinine, uric acid, 
glucose, total cholesterol, high density lipoprotein cholesterol (HDL-c), low density 
lipoprotein cholesterol (LDL-c), triglycerides, and high-sensitivity C-reactive protein (hs-
CRP). Analytes were originally measured in the entire cohort at each of the five visits, 
except for creatinine and uric acid, which were not measured at visit 3, and hs-CRP, which 
was not measured at visits 1 or 3. Seven additional analytes that were not remeasured at all 5 
study visits were also included in a secondary recalibration study: alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), N-
terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-
cTnT), β2-microglobulin (B2M) and beta-trace protein (BTP) (see Online Supplement for 
details).
Analytes were re-assayed at Baylor College of Medicine during 2011–13 (Figure 1). For 
each of the 200 participants in the recalibration subsample, measurements were obtained 
from stored samples from all 5 visits. Samples had been stored at −70 degrees Celsius since 
original collection, which took place during visits from 1987 to 2013. LDL-c was calculated 
from the concentrations of total cholesterol, HDL-c, and triglycerides by the Friedewald 
formula. See eTable 1 (all eTables are in the Online Supplement) for a detailed description 
of assay methodologies and approaches. When available, commutable certified reference 
materials (CRMs) were included with some of the assays to verify the traceability of 
measurement results to certified values of current high quality reference materials (eTable 
5).
Statistical analysis
Recalibration—For each analyte re-assayed in the recalibration subsample, we calculated 
descriptive statistics for the original value, the re-assayed value (in 2011–2013), and the 
difference of the two values. We calculated the percent bias for each analyte as:
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We recalibrated all previous measurement values to the most recent results of measurement 
procedures performed in 2011–2013. Scatterplots were used to visually compare 
measurement values. To remove outliers that were extraneous to the recalibration process, 
we used an iterative outlier removal process. This approach is based on the assumption that 
outliers (defined as differences >3 standard deviations from the mean difference) are likely 
due to a non-analytic error-related process, such as isolated sample degradation or data entry 
error, which would not be relevant to the recalibration. Briefly, observations greater than 3 
standard deviations from the mean difference were defined as outliers and removed. We 
then calculated the new standard deviation and mean in the new dataset and values >3 
standard deviations away from the mean difference were excluded. This procedure was 
repeated until no outliers remained. After exclusion of outliers, we conducted Deming 
regression of the original versus re-assayed measurement values (12,13). For analytes with 
differences >10%, recalibration equations were derived from the Deming regression 
coefficients.
Impact of Recalibration—We assessed trends in original values and recalibrated 
measurement values over time in the total study population, both unadjusted and adjusted 
for the following covariates: gender, race-center, body mass index, diabetes (self-reported 
physician diagnosis or medication use), current smoking status (current versus former/
never), and hypertension (diastolic blood pressure ≥90 mmHg, systolic blood pressure ≥140 
mmHg or antihypertensive use). We plotted the mean analyte value pre- and post-
recalibration by age at each visit (unadjusted graphs); as well as the predicted residual from 
the regression of the analyte value on the aforementioned covariates against age at each visit 
(adjusted graphs). We obtained the intercept (centered at the mean age at visit 1 [54 years]) 
and slope for the regression lines plotted for each analyte at each visit to enable quantitative 
comparison of trends over time across visits before and after recalibration.
We calculated estimated glomerular filtration rate (eGFR) (using both original values for 
and recalibrated creatinine) using the 2009 CKD Epidemiology Collaboration (CKD-EPI) 
creatinine equation, which requires use of isotope dilution mass spectrometry IDMS-
traceable creatinine measurements (14). We defined prevalent CKD (stage 3+) as eGFR<60 
mL/min/1.73 m2; and incident CKD (stage 3+) at visits 2, 4 and 5 as eGFR<60 mL/min/1.73 
m2 with an eGFR decline of ≥25% since visit 1. We compared the prevalence of CKD at 
visits 1, 2, 4 and 5 pre- and post-recalibration by estimating the proportion of participants 
with eGFR<60 mL/min/1.73 m2 at each visit. For comparison, we also calculated the 
prevalence of CKD at each visit using creatinine values that were recalibrated without 
having identified and excluded outliers. We calculated the incidence rate of CKD among 
persons with no CKD at visit 1 who attended visit 2, again comparing results before and 
after recalibration. We also compared the results to recalibration in previous studies, which 
largely relied on statistical, rather than laboratory recalibration. We will consider statistical 
recalibration to be recalibration based on statistics, in a setting in which analytes were not 
re-measured; and laboratory recalibration to be recalibration based on re-measurement of 
analytes.
All statistical analyses were conducted using Stata version 13.0 (StataCorp, College Station, 
Texas).
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Baseline Characteristics of the Recalibration Subsample
The distribution of age and gender in the 200-participant recalibration subsample was 
similar to that of the total ARIC cohort (Table 1). The recalibration subsample consisted of 
fewer white participants than the entire ARIC cohort (63% and 73%, respectively). Since 
inclusion in the recalibration subsample required attendance at all study visits during the 25 
years of follow-up, subsample participants tended to be healthier compared to the entire 
cohort. For example, at visit 1, participants in the subsample had a lower mean BMI (26.9 
versus 27.7 kg/m2 in the entire cohort) and a lower prevalence of current smoking (19% 
versus 26%), hypertension (24% versus 35%), and coronary heart disease (2% versus 5%).
Estimates of Bias in Original Values
Overall, there were 4.5% of paired measurement values that were considered outliers and 
removed using iterative outlier removal (described above). After removal of these outliers, 
re-assayed measurement values were highly correlated with original values (of 28 
comparisons of the 8 analytes across multiple visits, 43% had Pearson’s r>0.95 and 18% had 
r>0.99). Bias was <10% for all analytes except creatinine and uric acid (Table 2). Lipids, 
glucose and hs-CRP measurement values showed the lowest overall percent bias. Creatinine 
had particularly high bias: 49%, 47% and 13% at visits 1, 2 and 4, respectively. 
Comparisons of original and re-assay methods for HDL-c revealed substantial differences. 
However, we do not recommend recalibration of HDL-c across visits in the ARIC Study, 
since the method used to conduct assays at the most recent visit in 2011–13 (visit 5) and 
within the recalibration subsample was a direct enzymatic method, which differs 
substantially from magnesium dextran precipitation methodology used during visits 1–4 
(eTable 1).
Development and Application of Recalibration Equations
Based on descriptive statistics of original and new measurement values and Deming 
regression results (Table 2 and eTable 4), we developed recalibration equations for 
creatinine and uric acid at visits 1, 2, and 4. Recalibration equations were applied to the 
values in the entire cohort (Table 2).
Recalibration Effects on eGFR Trajectories
Trends in eGFR over time were substantially better aligned after recalibration equations 
were applied to the entire cohort (Figure 2, Panel A). The intercepts and slopes from the 
regression of mean eGFR on age by visit (centered at the mean age at visit 1 [54 years]) 
were more similar after recalibration. Intercepts ranged from 101.4 to 163.0 mL/min/1.73 
m2 before recalibration and 144.2 to 158.4 mL/min/1.73 m2 after recalibration; slopes 
ranged from −0.6 to −1.1 mL/min/1.73 m2 per year of age before recalibration and were 
nearly identical across visits at −1.0 mL/min/1.73 m2 per year of age after recalibration 
(Table 3). Similarly, trends in uric acid were improved after the recalibration equations were 
applied to the entire cohort (Figure 2, Panel B; Table 3).
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Recalibration Effects on CKD Prevalence and Incidence
Compared with the prevalence of CKD determined by eGFR from original values for 
creatinine at visits 1, 2, 4 and 5 (21.7%, 36.1%, 3.5%, and 29.4%, respectively), the 
prevalence of CKD from recalibrated creatinine at these same visits was 1.3%, 2.2%, 6.4%, 
and 29.4%. In comparison, statistical recalibration in previous papers yielded prevalences of 
1.9%, 3.6%, and 6.8% for visits 1, 2 and 4 (Figure 3). If we had recalibrated creatinine 
without removing any outliers, the prevalence estimates for CKD at each visit would have 
been higher than obtained using either the current recalibration or the previous statistical 
recalibration: 8.5%, 3.4%, and 6.5% for visits 1, 2 and 4, respectively. Among the 12,228 
participants with no CKD at baseline defined by eGFR calculated using either original or 
recalibrated creatinine values, 1,157 and 1,480 participants developed CKD using original 
values for creatinine and recalibrated creatinine, respectively. Among persons who had no 
CKD at baseline and attended visit 2, the incidence rate of CKD was 7.1 per 1,000 person-
years and 8.9 per 1,000 person-years, as defined by eGFR using original values for 
creatinine and recalibrated creatinine, respectively.
DISCUSSION
This rigorously performed laboratory recalibration study of blood analytes measured at 5 
study visits spanning approximately 25 years of data collection in the ARIC Study 
demonstrated that many measurements were equivalent over time and did not require 
recalibration. Correlations over time in values of re-measured analytes ranged from high to 
very high. We found substantial bias in 2 analytes (creatinine and uric acid), which we 
addressed by developing recalibration equations in a subsample and applying these 
recalibrations to the entire cohort. Using CKD as an example, we demonstrated that 
assuming equivalence of measurement values across time without confirmation by a 
rigorous recalibration study can result in substantial under- or overestimates of prevalence 
and incidence of disease. Additionally, the assay method for HDL-c was different during 
visit 5, suggesting comparison of HDL-c measurement values across visits in ARIC or other 
studies that include both a direct enzymatic and precipitation method has serious limitations. 
Although the direct HDL-c method did show good agreement with commutable CRMs in 
our study, the accuracy of direct measurement of HDL-c for risk classification has been 
called into question, especially in the setting of hypertriglyceridemia (15). Alternatively, it is 
possible that HDL-c measurement values using the direct enzymatic method during the 
recalibration study were affected by long-term sample storage (up to 25 years), since all 
original lipid analyses were performed on either fresh (visits 1–4) or short-term (<1 week) 
frozen samples (visit 5). There is a paucity of data on the effects of long-term sample storage 
on HDL-c measurement values by direct methods. For those analytes that did require 
recalibration, alignment of values across visits was achieved and will strengthen future 
longitudinal analyses in this cohort.
CKD was chosen as an important example since classification is based on laboratory 
assessment of an eGFR threshold, and accurate characterization of trajectories of eGFR is of 
direct clinical interest (16–20). The dramatic impact of creatinine recalibration on CKD 
estimates has been reported in previous studies (2,4,21). CKD prevalence and incidence 
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estimates before and after recalibration of creatinine can differ substantially. In our study, a 
naïve calculation of eGFR using original values for creatinine resulted in a substantial 
overestimate of the baseline CKD prevalence and underestimate of the CKD incidence rate. 
Baseline eGFR values were higher at visit 1 after recalibrating creatinine. Since the 
definition of incident CKD required a 25% or greater decline in eGFR since visit 1, a greater 
number of participants fulfilled these criteria after recalibration of creatinine. We noticed 
greater percent bias in creatinine at visits 1 and 2 when measurements were conducted in an 
era prior to the purposeful change in creatinine assay result traceability using isotope 
dilution reference measurement procedures (22). Whereas the evaluation of creatinine 
equivalence over time should be routine in studies of CKD trends, it is particularly important 
in studies such as ours, which span a long time period. Creatinine assay recalibration is 
known to have changed and inter-laboratory reproducibility has improved dramatically over 
the past decade (23).
Indirect statistical correction (as opposed to direct laboratory recalibration) may be 
implemented where re-assay of analytes is not feasible. This method may be achieved by 
selecting a “healthy subset” of the study population, in which the mean value of the analyte 
of interest, adjusted for any potential confounders, would be expected to be constant over 
time. Any significant deviation in mean analyte level over time would then be considered 
artifactual, and recalibration based on statistics achieved by normalizing to a particular 
reference year/time period. This technique has been successfully implemented in previous 
studies (5,6). Previous recalibration studies in ARIC were statistical in nature, rather than 
laboratory-based (24,25). Indeed, a previous statistical correction was used by ARIC 
investigators to recalibrate serum creatinine, by adjusting the serum creatinine values from 
the ARIC study population to have the same age, sex and race adjusted means as 
recalibrated NHANES data (24). The magnitude and direction of this statistical correction 
was reasonably similar to our direct recalibration (CKD prevalence of 1.9%, 3.6% and 6.8% 
at visits 1, 2 and 4 from previous statistical recalibration; compared to 21.7%, 36.1%, and 
3.5% using original values; and 1.3%, 2.2%, and 6.4% with laboratory recalibration). In 
settings where laboratory recalibration may not be feasible, statistical recalibration can 
provide insight into the magnitude of bias and provide an approach to minimizing it.
There were several key strengths of this study. First, ARIC enrolled nearly 16,000 
participants, which enabled calculation of precise estimates of CKD prevalence and 
incidence before and after application of recalibration equations to the full cohort. Second, 
ARIC is an ongoing prospective cohort study, which currently has approximately 25 years 
of follow-up. To date, there have been five visits, which allowed for comparison of trends 
over time before and after recalibration. Finally, our design was efficient and is potentially 
generalizable to other cohort studies, for which there may be interest in conducting 
laboratory recalibration studies in a practical and cost-effective manner.
Our study had several limitations. We assumed that the recalibration equations derived from 
the subset of 200 participants included in the recalibration subsample applied to the entire 
ARIC study population. These 200 samples may not have covered the entire range of values 
for each analyte, and there may be instances, especially at very low or very high values, in 
which the recalibration is an under- or overcorrection. Nonetheless, we were able to 
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demonstrate improved similarity of creatinine and uric acid measurement values across 
ARIC visits using this approach. Our approach also assumes that the biomarkers being 
measured were in fact stable at −70° C in the stored samples and that changes in 
measurement procedure results were not simply due to changes in the biomarker 
concentrations in the samples over time.
Recalibration of laboratory measures is a key concern for large epidemiologic studies, 
particularly when trends in disease prevalence and risk factors over long periods of time are 
of interest. Reasons for poor reproducibility of measurement values over time may include 
changes in laboratory measurement procedures, more subtle differences in pre-analytical 
specimen processing or laboratory technique, sample degradation during storage, sample 
evaporation due to poorly sealed vials, and/or use of different specimen types. However, 
laboratory recalibration over time assumes the analyte is stable at the storage conditions. 
High correlations and improvement after recalibration supports this assumption for all the 
analytes examined in the current study, but it is difficult to test for long storage periods. 
Although availability of follow-up data for many years can be a major strength of large 
cohort studies, ensuring equivalence of measurement values over a long duration of time is 
instrumental in achieving accurate analytic results. Periodic recalibration studies are 
required to determine if measurement values lack equivalence and to recommend 
appropriate corrections, if necessary. Traceability of values to stable references would be 
ideal. Whereas external high quality reference measurement procedures or commutable 
reference materials are not available for all analytes, they can at least be recalibrated to an 
internal reference for within-study comparisons over time. The techniques we used were 
standard laboratory and statistical analytic methods, and we encourage their use in large 
epidemiologic studies.
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Figure 1. Study design for original measurements in the entire ARIC cohort and re-assay of 
analytes in the recalibration subsample
Note that this schematic is an example, and details may vary by analyte. See eTable 1 for 
methods and assays used for each analyte.
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Figure 2. Regression of estimated GFR and uric acid versus age across five ARIC visits before 
and after applying the laboratory recalibration
To examine trends versus age across visit, the lines plotted are creatinine-based eGFR 
(Panel A1: original values, unadjusted; Panel A2: recalibrated, unadjusted; Panel A3: 
original values, adjusted; Panel A4: recalibrated, adjusted) and uric acid (Panel B1: original 
values, unadjusted; Panel B2: recalibrated, unadjusted; Panel B3: original values, adjusted; 
Panel B4: recalibrated, adjusted) regressed on age (separately for each visit). Adjusted 
analyses included adjustment for gender, race-center, body mass index, diabetes (self-
reported physician diagnosis or medication use), current smoking status (current versus 
former/never) and hypertension (diastolic blood pressure ≥90 mmHg, systolic blood 
pressure ≥140 mmHg or antihypertensive use). Recalibration allows us to remove 
differences in methodologic issues to the best of our ability and differences that remain are 
largely due to changes over time.
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Figure 3. Comparison of prevalence estimates of chronic kidney disease before and after 
recalibration of creatinine
Chronic kidney disease was defined as eGFR<60 mL/min/1.73 m2
Creatinine recalibration equations from a previous statistical recalibration were: 
(Original-0.24)*0.95 for visits 1 and 2; and (Original+0.18)*0.95 for visit 4
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Table 1
Clinical and sociodemographic characteristics of recalibration subsample and entire ARIC cohort at baseline 
(1987–89)
Baseline Characteristics Recalibration Subsample (N=200) Entire ARIC cohort (N=15,792)
Mean (SD) or N (%) Mean (SD) or N (%)
Age, years 53.0 (5.4) 54.2 (5.8)
Male 96 (48%) 7,082 (45%)
Race/ethnicity
 White 126 (63%) 11,478 (73%)
 Black 74 (37%) 4,266 (27%)
 Other 0 (0%) 48 (0%)
Education
 Less than high school 30 (15%) 3,767 (24%)
 High school or college 76 (38%) 6,412 (41%)
 More than college 92 (47%) 5,586 (35%)
Study site
 Forsyth, NC 54 (27%) 4,035 (26%)
 Jackson, MS 61 (30.5%) 3,728 (24%)
 Minneapolis, MN 45 (22.5%) 4,009 (25%)
 Washington County, MD 40 (20%) 4,020 (25%)
Body mass index, kg/m2 26.9 (4.5) 27.7 (5.4)
Current smoking 38 (19%) 4,132 (26%)
Hypertension 47 (24%) 5,504 (35%)
Prevalent coronary heart disease 4 (2%) 766 (5%)
3 participants missing hypertension status; 1 participant missing prevalent CHD status; 2 participants missing education level
Hypertension defined as diastolic blood pressure>90 mmHg or systolic blood pressure>140 or anti-hypertensive medication use
Prevalent coronary heart disease defined as history of MI, MI from ECG, history of heart/arterial surgery, coronary bypass or angioplasty
In the entire ARIC cohort, 16 missing smoking status; 80 missing hypertension status; 344 missing prevalent CHD status; 27 participants missing 
education level
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